A medication assessment tool to evaluate prescribers’ adherence to evidence-based guidelines in bipolar disorder

International Journal of Clinical Pharmacy

Volumn 39, Issue 4, 2017, Pages 897-905

  Al Taweel, Dalal M ^a   Alsuwaidan, Mohammad ^a,b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Clinical guidelines; Guideline adherence; Kuwait; Medication therapy management

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; CARBAMAZEPINE; LAMOTRIGINE; LEVETIRACETAM; LITHIUM; LURASIDONE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PRAMIPEXOLE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTENT VALIDITY; CONTENT VALIDITY INDEX; CONTENT VALIDITY RATIO; CROSS-SECTIONAL STUDY; DEPRESSION; EMERGENCY CARE; EVIDENCE BASED PRACTICE; FACE VALIDITY; FEASIBILITY STUDY; FEMALE; HUMAN; KUWAIT; LIKERT SCALE; MALE; MEDICAL EXPERT; MEDICATION ASSESSMENT TOOL; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; PSYCHIATRY; RELIABILITY; RETROSPECTIVE STUDY; VALIDATION STUDY; YOUNG ADULT; MEDICATION THERAPY MANAGEMENT; PHARMACIST; PHYSICIAN; REPRODUCIBILITY; STANDARDS;

ADULT; BIPOLAR DISORDER; DRUG PRESCRIPTIONS; FEASIBILITY STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; PHARMACISTS; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 85021283777     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-017-0498-3     Document Type: Article

References (23)

1. Department of Health. High quality care for all–NHS Next stage review final report. 2008 UK.
2. President’s advisory commission on consumer protection and quality in the health care industry. Quality first: better health care for all Americans—final report to the President of the United States. 1998 Washington, Government Printing Office.
3. Boland EM, Alloy LB. Sleep disturbance and cognitive deficits in bipolar disorder: toward an integrated examination of disorder maintenance and functional impairment. Clin Psychol Rev. 2013;33:33–44.
4. Ösby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.
5. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293:2528–30.
6. Kleinman LS, Lowin A, Flood E, Gandhi G, Edgell E, Revicki DA. Costs of bipolar disorder. PharmacoEconomics. 2003;21:601–22.
7. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord. 2011;129:79–83.
8. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve month use of mental health services in the United States. Arch Gen Psychiatry. 2005;62:629–40.
9. Dawda Y. Bipolar affective disorder: long-term management.Clinical pharmacist. 2009:73–82.
10. Drayton SJ, Pelic CM. Bipolar Disorder. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach, 9e. New York: The McGraw-Hill Companies; 2014. Chapter 52.
11. Kamyar M, Johnson BJ, McAnaw JJ, Lemmens-Gruber R, Hudson SA. Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. Pharm World Sci. 2008;30:120–7.
12. Garcia BH, Utnes J, Naalsund LU, Giverhaug T. MAT-CHDSP, a novel medication assessment tool for evaluation of secondary prevention of coronary heart disease. Pharmacoepidemiol Drug Saf. 2011;20:249–57.
13. Hakonsen GD, Hudson S, Loennechen T. Design and validation of a medication assessment tool for cancer pain management. Pharm World Sci. 2006;28:342–51.
14. Al-Taweel DM, Awad AI, Johnson BJ. Evaluation of adherence to international guidelines for treating patients with type 2 diabetes mellitus in Kuwait. Int J Clin Pharm. 2013;35:244–50.
15. Dennehy EB, Suppes T, Rush AJ, Miller AL, Trivedi MH, Crismon ML, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med. 2005;35:1695–706.
16. Suppes T, Rush AJ, Dennehy EB, Crismon ML, Kashner TM, Toprac MG, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. J Clin Psychiatry. 2003;64:370–82.
17. Wang Z, Gao K, Hong W, Xing M, Wu Z, Chen J, et al. Guidelines disconcordance in acute bipolar depression: data from the National Bipolar Mania Pathway Survey (BIPAS) in mainland China. PLoS ONE. 2014. doi:10.1371/journal.pone.0096096.
18. Perlis RH. Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Curr Med Res Opin. 2007;23:467–75.
19. Divac N, Marić NP, Damjanović A, Jovanović AA, Jašović-Gašić M, Prostran M. Use or underuse of therapeutic guidelines in psychiatry? Psychiatr Danub. 2009;21:224–9.
20. Samalin L, Guillaume S, Auclair C, Llorca P-M. Adherence to guidelines by French psychiatrists in their real world of clinical practice. J Nerv Ment Dis. 2011;199:239–43.
21. Paterniti S, Bisserbe JC. Pharmacotherapy for bipolar disorder and concordance with treatment guidelines: survey of a general population sample referred to a tertiary care service. BMC Psychiatr. 2013;13:211.
22. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1–44.
23. National institute for health and care excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]; 2014; Updated Feb 2016.